Reduced Taurine Transporter Expression in Lymphoblastoid Cell Lines From Alzheimer's Disease Patients Compared With Age‐Matched Controls: Therapeutic Implications?
Drug Development Research · 2025
DOI: 10.1002/ddr.70124 ↗Kurz gefasst
Fachartikel in der Zeitschrift Drug Development Research, 2025. Verfasst von Yuval Gavriel und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Human Molecular Genetics and Biochemistry, Gray Faculty of Health and Medical Sciences, Tel Aviv University, Tel Aviv, Israel. Hauptthemen laut MEDLINE: Alzheimer Disease, Membrane Transport Proteins, Taurine, Membrane Glycoproteins. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 69 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: The authors received no specific funding for this work..
Themen: Demenz
Abstract (Originalsprache)
Taurine is an atypical amino acid that cannot form peptide bonds and thus does not take place in building proteins. Yet, taurine takes part in regulating many cell functions, including cell osmolarity and volume, mitochondrial function, membrane ion channels and neuronal activity, and cell survival. Taurine is synthesized by the liver, and available from consumption of meat and fish, but not plants. It has millimolar concentrations in the brain, skeletal muscle, blood, heart, retina, and other tissues. Taurine is transported from the liver (following synthesis) or the intestine (following consumption) to blood by the taurine transporter, encoded in humans by SLC6A6 . A recent study reported that blood taurine declines dramatically in aged individuals. Several studies indicated that dietary taurine slows cognitive decline in Alzheimer's disease (AD) model mice. We therefore measured SLC6A6 mRNA expression in human lymphoblastoid cell lines (LCLs) from AD patients and age‐matched controls and observed 2.8‐fold lower expression in AD LCLs ( p = 0.0005). Additionally, glutathione peroxidase 1 ( GPX1 ), a key free‐radical scavenging selenoenzyme, had reduced mRNA expression in LCLs from AD patients compared with controls. Our observations suggest that reduced taurine transporter expression may contribute to AD pathogenesis and that dietary taurine might be beneficial for slowing disease progression in early‐stage AD. Clinical trials with dietary taurine supplementation of individuals with mild cognitive impairment (MCI) or early‐stage AD are required to assess its tentative therapeutic potential.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Human Molecular Genetics and Biochemistry, Gray Faculty of Health and Medical Sciences, Tel Aviv University, Tel Aviv, Israel.
- Department of Cell and Developmental Biology, Gray Faculty of Health and Medical Sciences, Tel Aviv University, Tel Aviv, Israel.
- Department of Biomedical Sciences, University of Cagliari, Cagliari, Italy.
- Sagol School of Neuroscience, Tel Aviv University, Tel Aviv, Israel.
ORCID-Profile: Irena Voinsky, Alessio Squassina, David Gurwitz
Förderung
- The authors received no specific funding for this work.
Zitieren
APA
Gavriel, Y., Voinsky, I., Klin, H., Squassina, A., & Gurwitz, D. (2025). Reduced Taurine Transporter Expression in Lymphoblastoid Cell Lines From Alzheimer's Disease Patients Compared With Age‐Matched Controls: Therapeutic Implications?. Drug Development Research. https://doi.org/10.1002/ddr.70124
Vancouver
Gavriel Y, Voinsky I, Klin H, Squassina A, Gurwitz D. Reduced Taurine Transporter Expression in Lymphoblastoid Cell Lines From Alzheimer's Disease Patients Compared With Age‐Matched Controls: Therapeutic Implications?. Drug Development Research. 2025. doi:10.1002/ddr.70124
BibTeX
@article{Gavriel2025,
author = {Gavriel, Yuval and Voinsky, Irena and Klin, Hana and Squassina, Alessio and Gurwitz, David},
title = {Reduced Taurine Transporter Expression in Lymphoblastoid Cell Lines From Alzheimer's Disease Patients Compared With Age‐Matched Controls: Therapeutic Implications?},
journal = {Drug Development Research},
year = {2025},
doi = {10.1002/ddr.70124}
}
EUVIMED